EMA Recommends Approval of Orforglipron for Obesity and Diabetes
European regulators have recommended approving orforglipron, a once-daily oral non-peptide GLP-1 receptor agonist developed by Lilly under the brand name Foundayo, for weight management and type-2 diabetes. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued the positive opinion, placing the pill as a potential alternative to injectable and other oral therapies.
-
Key Clinical Takeaways:
- Orforglipron is a once-daily oral non-peptide GLP-1 receptor agonist intended for weight management and type-2 diabetes.
- The CHMP recommendation covers adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27 to < 30) with at least one weight-related comorbidity, as well as type-2 diabetes patients.
- Phase 3 clinical trial programs, including ATTAIN and ACHIEVE, involved more than 10,000 participants.
CHMP Recommendation Details for Weight Management and Diabetes
The CHMP recommendation for weight management targets adults with obesity or those classified as overweight who present with at least one weight-related condition. Treatment requires pairing with a reduced-calorie diet and increased physical activity. For type-2 diabetes, the indication covers adults whose blood sugar remains uncontrolled through diet and exercise alone. According to the EMA announcement, orforglipron can function as a monotherapy when metformin is unsuitable, or serve in combination with other glucose-lowering medications.
Phase 3 Trial Results and Efficacy Data
Lilly’s regulatory submission rests on the ATTAIN program for obesity and the ACHIEVE program for type-2 diabetes. In the weight management studies encompassing over 4,740 participants, individuals treated with orforglipron for 72 weeks lost approximately 5 to 11 percent of their body weight depending on the dosage, compared to 2 to 2.5 percent for the placebo groups. For the type-2 diabetes indication across four studies with 3,765 participants, researchers tracked HbA1c reductions of 1.2 to 1.9 percent. Comparatively, placebo groups showed reductions of 0.4 to 0.8 percent, dapagliflozin 10 mg achieved 0.8 percent, and oral semaglutide showed reductions between 1.2 and 1.5 percent.
Non-Peptide GLP-1 Agonist Suppresses Appetite with Gastrointestinal Side Effects
As a low-molecular-weight non-peptide GLP-1 receptor agonist, orforglipron activates the GLP-1 receptor to suppress appetite, enhance satiety, and stimulate glucose-dependent insulin secretion while reducing glucagon release. Patients can take the pill at any time of day, with or without food. Treatment initiates at a low dose before stepping up based on patient response and tolerability. The most frequently observed adverse events included nausea, vomiting, and diarrhea. These gastrointestinal symptoms occurred primarily during the dose-escalation phase and decreased as treatment continued.
Next Steps in the European Regulatory Process
The positive opinion from the CHMP marks an intermediate milestone in the centralized EU approval pathway. The European Commission will review the recommendation to issue a legally binding, EU-wide marketing authorization. Individual member states will subsequently negotiate pricing and reimbursement frameworks.